Provectus Biopharmaceuticals Performance
| PVCTDelisted Stock | USD 0.11 0.00 0.00% |
The company holds a Beta of -4.12, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Provectus Biopharmaceutica are expected to decrease by larger amounts. On the other hand, during market turmoil, Provectus Biopharmaceutica is expected to outperform it. Provectus Biopharmaceutica right now holds a risk of 0.0%. Please check Provectus Biopharmaceutica value at risk, as well as the relationship between the skewness and relative strength index , to decide if Provectus Biopharmaceutica will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Provectus Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, Provectus Biopharmaceutica is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 97.2 K |
Provectus |
Provectus Biopharmaceutica Relative Risk vs. Return Landscape
If you would invest 11.00 in Provectus Biopharmaceuticals on January 26, 2024 and sell it today you would earn a total of 0.00 from holding Provectus Biopharmaceuticals or generate 0.0% return on investment over 90 days. Provectus Biopharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than Provectus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Provectus Biopharmaceutica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Provectus Biopharmaceutica's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Provectus Biopharmaceuticals, and traders can use it to determine the average amount a Provectus Biopharmaceutica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| PVCT |
Based on monthly moving average Provectus Biopharmaceutica is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Provectus Biopharmaceutica by adding Provectus Biopharmaceutica to a well-diversified portfolio.
Provectus Biopharmaceutica Fundamentals Growth
Provectus OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Provectus Biopharmaceutica, and Provectus Biopharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Provectus OTC Stock performance.
| Return On Asset | -1.85 | ||||
| Operating Margin | (4.77) % | ||||
| Current Valuation | 46.73 M | ||||
| Shares Outstanding | 419.55 M | ||||
| Price To Earning | (0.48) X | ||||
| Price To Book | 5.44 X | ||||
| Price To Sales | 55.94 X | ||||
| EBITDA | (4.56 M) | ||||
| Cash And Equivalents | 84.27 K | ||||
| Total Debt | 2.29 M | ||||
| Debt To Equity | 0.25 % | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (1.01 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Total Asset | 3.51 M | ||||
| Retained Earnings | (180.8 M) | ||||
| Current Asset | 14.72 M | ||||
| Current Liabilities | 4.12 M | ||||
About Provectus Biopharmaceutica Performance
To evaluate Provectus Biopharmaceutica OTC Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Provectus Biopharmaceutica generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Provectus OTC Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Provectus Biopharmaceutica market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Provectus's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee. Provectus Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.Things to note about Provectus Biopharmaceutica performance evaluation
Checking the ongoing alerts about Provectus Biopharmaceutica for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Provectus Biopharmaceutica help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Provectus Biopharmaceutica is not yet fully synchronised with the market data | |
| Provectus Biopharmaceutica has some characteristics of a very speculative penny stock | |
| Provectus Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| The company currently holds 2.29 M in liabilities with Debt to Equity (D/E) ratio of 0.25, which may suggest the company is not taking enough advantage from borrowing. Provectus Biopharmaceutica has a current ratio of 0.26, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Provectus Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Provectus Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Provectus Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Provectus to invest in growth at high rates of return. When we think about Provectus Biopharmaceutica's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (5.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Provectus Biopharmaceuticals currently holds about 84.27 K in cash with (1.01 M) of positive cash flow from operations. |
- Analyzing Provectus Biopharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Provectus Biopharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining Provectus Biopharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Provectus Biopharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Provectus Biopharmaceutica's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Provectus Biopharmaceutica's otc stock. These opinions can provide insight into Provectus Biopharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Provectus OTC Stock
If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| CEOs Directory Screen CEOs from public companies around the world |